CU20180025A7 - Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue - Google Patents

Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue

Info

Publication number
CU20180025A7
CU20180025A7 CU2018000025A CU20180025A CU20180025A7 CU 20180025 A7 CU20180025 A7 CU 20180025A7 CU 2018000025 A CU2018000025 A CU 2018000025A CU 20180025 A CU20180025 A CU 20180025A CU 20180025 A7 CU20180025 A7 CU 20180025A7
Authority
CU
Cuba
Prior art keywords
dengue virus
preparation
against dengue
tetravalent vaccine
tetravalent
Prior art date
Application number
CU2018000025A
Other languages
English (en)
Other versions
CU24579B1 (es
Inventor
Neuza Maria Frazatti Gallina
Original Assignee
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Butantan filed Critical Fund Butantan
Publication of CU20180025A7 publication Critical patent/CU20180025A7/es
Publication of CU24579B1 publication Critical patent/CU24579B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>Proceso para preparar una vacuna tetravalente atenuada contra el virus del dengue y producto del mismo. La presente invención también se refiere a un proceso de preparación de una vacuna tetravalente contra el dengue para su administración a un sujeto, a un método para inducir una respuesta inmune contra los serotipos 1, 2, 3 y 4 del virus del dengue en un paciente y a un kit para una vacuna tetravalente contra el dengue.</p>
CU2018000025A 2015-09-08 2016-09-06 Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue CU24579B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/847,422 US10004795B2 (en) 2015-09-08 2015-09-08 Process for preparing an attenuated tetravalent dengue vaccine
PCT/BR2016/050224 WO2017041156A1 (en) 2015-09-08 2016-09-06 Process for preparing an attenuated tetravalent dengue vaccine

Publications (2)

Publication Number Publication Date
CU20180025A7 true CU20180025A7 (es) 2018-11-06
CU24579B1 CU24579B1 (es) 2022-02-04

Family

ID=56268413

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000025A CU24579B1 (es) 2015-09-08 2016-09-06 Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue

Country Status (17)

Country Link
US (2) US10004795B2 (es)
EP (1) EP3347043B1 (es)
JP (1) JP6968070B2 (es)
CN (1) CN108289945B (es)
AR (1) AR105966A1 (es)
AU (1) AU2016318349B2 (es)
BR (1) BR102015030332B1 (es)
CL (1) CL2018000609A1 (es)
CO (1) CO2018003451A2 (es)
CR (1) CR20180202A (es)
CU (1) CU24579B1 (es)
EC (1) ECSP18026090A (es)
ES (1) ES3066529T3 (es)
MX (2) MX390304B (es)
PE (1) PE20181135A1 (es)
TW (1) TWI733694B (es)
WO (1) WO2017041156A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177574C (en) 2013-03-15 2026-03-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for dengue virus chimeric constructs in vaccines
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
JP7261239B2 (ja) * 2017-10-16 2023-04-19 セラム インスティチュート オブ インディア プライベイト リミテッド 弱毒生組換えフラビウイルスなどから成る安定したワクチン組成物およびその調製方法
IL316312A (en) 2017-12-07 2024-12-01 Merck Sharp ַ& Dohme Llc Dengue virus vaccine compound formulations
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11590221B2 (en) 2018-09-05 2023-02-28 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
EP4308695A4 (en) * 2021-03-19 2025-07-30 Merck Sharp & Dohme Llc UPSTREAM, CLOSED-CIRCUIT MANUFACTURING PROCESS FOR THE PRODUCTION OF DENGUE VIRUS
WO2023044774A1 (en) * 2021-09-24 2023-03-30 Sichuan Clover Biopharmaceuticals, Inc. Tpo mimetic fusion proteins and methods of use submission of sequence listing as ascii text file
EP4469177A2 (en) * 2022-01-25 2024-12-04 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001046061A (ja) * 1999-08-04 2001-02-20 Handai Biseibutsubiyou Kenkyukai 弱毒デングウイルス及びこれを用いるデング熱ワクチン
ES2355719T3 (es) * 2002-05-03 2011-03-30 The United States Government As Represented By The Department Of Health And Human Services Vacuna contra el dengue que contiene una deleción común de 30 nucleótidos en la utr en 3' del dengue tipos 1 y 2.
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
BRPI0417775A (pt) * 2003-12-19 2007-03-20 Wyeth Corp meio de congelamento de células livre de soro; processo para gerar um banco de células vero estável livre de soro; e banco de célula vero estável livre de soro
WO2006066332A1 (en) * 2004-12-23 2006-06-29 Murray Goulburn Co-Operative Co Limited Method of manufacture of a modified milk powder suitable as a rennet casein extender or replacer
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
AU2014240246B2 (en) * 2008-12-05 2017-08-10 Takeda Vaccines, Inc. Compositions, methods and uses for inducing viral growth
CA3177574C (en) * 2013-03-15 2026-03-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for dengue virus chimeric constructs in vaccines
US10023626B2 (en) * 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine

Also Published As

Publication number Publication date
TW201718008A (zh) 2017-06-01
US20180256702A1 (en) 2018-09-13
ES3066529T3 (en) 2026-05-13
CU24579B1 (es) 2022-02-04
JP6968070B2 (ja) 2021-11-17
CR20180202A (es) 2018-08-10
HK1258584A1 (en) 2019-11-15
CO2018003451A2 (es) 2018-11-30
JP2018527408A (ja) 2018-09-20
PE20181135A1 (es) 2018-07-17
AR105966A1 (es) 2017-11-29
US20170065701A1 (en) 2017-03-09
MX2021013109A (es) 2021-11-17
BR102015030332B1 (pt) 2019-11-05
ECSP18026090A (es) 2018-10-31
EP3347043C0 (en) 2026-01-07
AU2016318349A1 (en) 2018-04-19
EP3347043B1 (en) 2026-01-07
AU2016318349B2 (en) 2019-10-17
WO2017041156A1 (en) 2017-03-16
US10004795B2 (en) 2018-06-26
MX2018002901A (es) 2018-09-18
EP3347043A1 (en) 2018-07-18
US10201600B2 (en) 2019-02-12
CN108289945B (zh) 2022-05-31
TWI733694B (zh) 2021-07-21
CN108289945A (zh) 2018-07-17
CL2018000609A1 (es) 2018-08-17
BR102015030332A2 (pt) 2016-07-05
MX390304B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
CO2018003451A2 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
EP4218807A3 (en) Zika virus vaccine
ECSP18001613A (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
PH12018500127A1 (en) Vaccine compositions
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
MX381617B (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
MX2024003337A (es) Composiciones inmunogenicas contra la influenza.
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
MX2018006500A (es) Virus vivo que tiene un banco de cepas atenuadas del virus del dengue, y una vacuna contra el dengue que contiene el mismo como antigenos.
MX2024007379A (es) Vacunas para el virus del papiloma humano y metodos para su uso.